Behind the Money

When international private equity groups first entered Japan at the turn of the 21st century, newspapers criticised them as vulture funds and politicians steered clear of public contact. Today, it’s a different story. Dozens of buyout groups have set up in the country and the establishment is courting them. The FT’s Tokyo correspondent David Keohane and Tokyo bureau chief Leo Lewis explain why there’s been a shift, and how private equity’s presence may rejuvenate Japanese corporates. Clips from Toho. The FT does not use generative AI to voice its podcasts.- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:Is Japan private equity’s next frontier?Buyout firms play the long game beyond TokyoInvestors sense this time is different for JapanKKR-owned auto parts supplier Marelli files for US bankruptcy protection - - - - - - - - - - - - - - - - - - - - - - - - - - Follow David Keohane (@DavidKeo) and Leo Lewis (@Urbandirt) on X. Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. - - - - - - - - - - - - - - - - - - - - - - - - - -  To sign up for free to the new FT Alphaville newsletter on substack, go to ftav.substack.comRead a transcript of this episode on FT.com

Investors are spending billions of dollars on novel ways to extend human life through inventive treatments, therapies, and even manipulating our genes. And increasingly, it seems as though anti-ageing efforts have moved from the super rich to a mass market consumer industry. In this series, we’re covering the past, present and future of the longevity movement. We’ll be looking at where the fixation on longevity is coming from, and trying to understand the practical and ethical issues at the heart of this cutting-edge field of research. From Silicon Valley fantasies, to Singaporean health spas, to Colombian genetic clinics and beyond, the FT’s Hannah Kuchler and Michael Peel ask whether breakthroughs in science and technology can really help us live longer, and even stop us aging altogether.Free to read: US ‘wellness’ industry scents opportunity to go mainstreamThe quest to make young blood into a drugThis season of Tech Tonic was produced by Josh Gabert-Doyon. The senior producer is Edwin Lane. Flo Phillips is the executive producer. Sound design by Breen Turner and Samantha Giovinco. Fact checking by Simon Greaves, Lucy Baldwin and Tara Cromie. Original music by Metaphor Music. Manuela Saragosa is the FT’s acting co-head of audio.The FT does not use generative AI to voice its podcasts.

OpenAI is entering a new era. It's restructured to add a for-profit arm to its business and has signed more than a trillion dollars’ worth of deals to secure chips and build out data centres. But those huge financial commitments also raise massive questions: How will a heavily loss-making company fund $1.4tn worth of deals with some of the biggest publicly listed companies in the world? And what systemic risks could that come with? The FT's US west coast financial editor Tabby Kinder and venture capital correspondent George Hammond answer the questions everyone's asking.The FT does not use generative AI to voice its podcasts.Clips from Bg2 Pod, CNBC, Yahoo Finance- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:How OpenAI put itself at the centre of a $1tn network of dealsWho owns OpenAI? Blockbuster deals complicate investor payoutsOpenAI shunned advisers on $1.5tn of dealsHow high are OpenAI’s compute costs? Possibly a lot higher than we thought- - - - - - - - - - - - - - - - - - - - - - - - - - Attend the FT Global Banking Summit, December 2-4 in London: Enter SAVE20 for a 20% discount, register here.- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Tabby Kinder (@Tabby_Kinder) and George Hammond (@GeorgeNHammond) on X or on Bluesky (@tabbykinder.bsky.social), (@georgehammond.bsky.social). Behind the Money host Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. Read a transcript of this episode on FT.com

Pharma juggernauts Pfizer and Novo Nordisk are struggling in the obesity drug race.The two companies are searching for their next moneymaker, and that search recently spun out into a ferocious, multibillion-dollar battle for control of biotech start-up Metsera. The FT’s US deals and activism correspondent Oliver Barnes walks through the tussle that’s involved lawsuits, public barbs and political drama.Clips from CNBC, Pfizer, Yahoo Finance- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading and listening:Weight-loss wars: $10bn hostile battle pits Pfizer against Novo NordiskPfizer shows hardball mettle needed to win in 2025 M&AThere is only one winner in the Pfizer Novo Nordisk showdownOzempic’s unconventional origins- - - - - - - - - - - - - - - - - - - - - - - - - - Attend the FT Global Banking Summit, 2-4 December in London: Enter SAVE20 for a 20% discount, register here.- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Oliver Barnes on X (@mroliverbarnes), or on Bluesky (@mroliverbarnes.bsky.social) Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more.Read a transcript of this episode on FT.com

Publicly-listed Oklo sits at the intersection of two hot areas for Wall Street: artificial intelligence and energy companies. This year alone, Oklo’s share price has jumped more than 400 per cent. But the business hasn’t generated any revenue. It hasn’t built a nuclear reactor, and it hasn’t secured any binding contracts with customers. The FT’s US energy editor Jamie Smyth explains the enthusiasm for Oklo, its links to the Trump administration and whether it can live up to the hype.Clips from New York Stock Exchange, The White House, a16z- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:Inside Oklo: the $20bn nuclear start-up without any revenueUS and investors gambling on unproven nuclear technology, warn expertsDonald Trump’s assault on US nuclear watchdog raises safety concerns- - - - - - - - - - - - - - - - - - - - - - - - - - Attend the FT Global Banking Summit, 2-4 December in London: Enter SAVE20 for a 20% discount, register here.- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Jamie Smyth on X (@JamieSmythF), or on Bluesky (@jamiesmythft.bsky.social). Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. Read a transcript of this episode on FT.com

Some of the world’s biggest financial institutions are reeling after the collapse of a little-known car parts supplier: First Brands Group. The company filed for bankruptcy last month, and since then, FT reporters have shone a spotlight on billions of dollars of hidden debt and a secretive founder whose borrowing habits left creditors exposed. The FT’s corporate finance editor Robert Smith and banking editor Ortenca Aliaj walk through their investigation and explain how this event has raised questions about potential cracks in private credit.  - - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:The secretive First Brands founder, his $12bn debt and the future of private creditFirst Brands Group: dude, where’s my cash?First Brands bankruptcy: the losers — and winners- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Robert Smith on X (@BondHack), or on Bluesky (@bondhack.ft.com). Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. Read a transcript of this episode on FT.com

The world’s largest listed hedge fund manager, Man Group, is at a crossroads. After years of high flying thanks to its innovative quant trading strategies, the company’s hedge fund unit has been faltering. Recently, the performance of Man Group’s core business has been lacklustre, and some institutional investors have pulled their money. The FT’s hedge fund correspondent Costas Mourselas analyses which strategies Man Group may pursue to rebound. - - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:Can the world’s largest listed hedge fund rebound?Man Group’s hedge fund bluesRobyn Grew: the ‘force of nature’ named Man Group chief executive- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Costas Mourselas on X (@CostasMourselas). Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more. Read a transcript of this episode on FT.com

Introducing Toxic Legacy, a new season of Untold from the Financial Times. Host Laura Hughes uncovers a lead poisoning epidemic across the UK. You might be living with lead and not know it: the toxin is often invisible to the human eye, but wreaks havoc on our bodies once we’re exposed. The first episode of Untold: Toxic Legacy launches October 22. Listen on Apple Podcasts, Spotify, Pocket Casts or wherever you get your podcasts.For information on how to live safely with lead, please visit the LEAPP Alliance website.

From KitKat candy bars to Perrier mineral water, Nestlé owns thousands of brands. But recently the world’s largest food and beverage company has severely underperformed its rivals in the wider consumer goods sector. The business is also emerging from a scandal involving its most recent chief executive. The FT’s consumer industries reporter Madeleine Speed explains how Nestlé’s challenges fit into an industry under pressure from shareholders, and what plans the group’s new leadership are considering. Clips from TBS/YouTube and Nestlé- - - - - - - - - - - - - - - - - - - - - - - - - - For further reading:The meltdown at NestléNestlé’s CEO ousting makes case for corporate ‘veep’Denials and defiance: Nestlé chief’s exit over relationship prompts investor unrest- - - - - - - - - - - - - - - - - - - - - - - - - - Follow Madeleine Speed on X (@SpeedMaddie). Michela Tindera is on X (@mtindera07) and Bluesky (@mtindera.ft.com), or follow her on LinkedIn for updates about the show and more.Read a transcript of this episode on FT.com